What if tumour cells could be reprogrammed to help organise the very immune responses needed to destroy them?
A new study published in Immunity identifies a strategy that converts tumour cells into type 1 conventional dendritic cell-like cells (cDC1-like cells), driving the formation of immunogenic tertiary lymphoid structures (TLSs) within tumours (Figure 1).
TLSs are organised immune cell aggregates that can develop in tumour tissue. They provide local environments for T- and B-cell interactions and are associated with improved responses to cancer immunotherapy.
By reprogramming tumour cells into cDC1-like cells, the researchers induced immunogenic TLSs across several cancer models, including melanoma, colorectal, bladder, breast and pancreatic cancer.
These reprogrammed cells:
- Activated lymphotoxin, TNF and interferon signalling programmes.
- Engaged T cells through MHC class I and CD40 signalling, initiating TLS formation.
- Established organised immune niches containing CD4+ and CD8+ T cells, as well as B cells.
- Supported TLSs containing BCL6+ germinal centres, important sites of B-cell maturation and antibody responses.
The researchers also identified distinct spatial roles for resident and migratory cDC1-like cells, with DC-LAMP+ CCR7+ migratory cells helping to organise these immune niches.
Importantly, the immunogenic TLSs supported both T- and B-cell responses and promoted systemic anti-tumour immunity. The researchers observed expansion of shared immune-cell clonotypes in distant, untreated tumours, suggesting that locally reprogramming tumour cells could help generate broader immune responses.
Although TLSs are associated with better immunotherapy outcomes, inducing their formation remains a challenge. This study suggests that cellular reprogramming could provide a way to remodel the tumour microenvironment, establish organised immune hubs and potentially overcome resistance to immunotherapy.
The findings are promising, but further work is needed to establish how this strategy could be translated into safe and effective treatments for patients.
Journal article: Ascic, E., et al. 2026. Tumor-to-dendritic cell reprogramming induces immunogenic lymphoid structures across cancers. Immunity.
Summary by Stefan Botha











